Johnson & Johnson market cap JNJ
Share price times shares outstanding: what the whole company sells for, since 2009.
- Today, Oct 23, 2026
- $635.8B
- Highest close in our data
- $663.3B
- Sep 2026
Johnson & Johnson is worth $635.8B at the close on Oct 23, 2026, at $263.81 a share.
That is up 39% over the last year and up 48% over five years.
Its highest close in our data was $663.3B in Sep 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $635.8B | $492.4B | $663.3B | +27% |
| 2025 | $500.2B | $342B | $509.8B | +43% |
| 2024 | $349.2B | $347.8B | $399.3B | −7% |
| 2023 | $377.3B | $354.5B | $471.3B | −18% |
| 2022 | $461.8B | $421.2B | $479.7B | +3% |
| 2021 | $450.4B | $410.3B | $472.4B | +9% |
| 2020 | $414.3B | $315.9B | $414.3B | +8% |
| 2019 | $383.6B | $337B | $384.4B | +12% |
| 2018 | $341.3B | $325.2B | $395.9B | −9% |
| 2017 | $375.4B | $308.5B | $382.7B | +20% |
| 2016 | $313.4B | $267.7B | $344.5B | +10% |
| 2015 | $284.2B | $252B | $293.7B | −3% |
| 2014 | $294.1B | $249.6B | $304.6B | +13% |
| 2013 | $260.6B | $198.3B | $268.7B | +35% |
| 2012 | $192.5B | $169.7B | $198.1B | +8% |
| 2011 | $179.1B | $160.2B | $185.2B | +5% |
| 2010 | $169.9B | $158.7B | $181B | −4% |
| 2009 | $177.7B | $162.7B | $178.9B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.
| Company | Market cap |
|---|---|
| JNJJohnson & Johnson | $635.8B |
| ABBVAbbVie | $504.8B |
| MRKMerck | $358.4B |
| LLYEli Lilly and | $1.2T |
| AMGNAmgen | $237.5B |
| GILDGilead Sciences | $193.5B |
| PFEPfizer | $171.2B |
| BMYBristol-Myers Squibb | $125.6B |
| Peer median | $237.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Johnson & Johnson
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.